Certolizumab pegol

From Wikipedia, the free encyclopedia

The introduction to this article provides insufficient context for those unfamiliar with the subject matter.
Please help improve the introduction to meet Wikipedia's layout standards. You can discuss the issue on the talk page.

Certolizumab pegol (CDP870) is a PEGylated Fab' fragment of a humanized anti-TNF-alpha monoclonal antibody. It is the subject of phase III clinical trials in both Crohn's disease and rheumatoid arthritis. Significant positive results have been demonstrated for two pivotal phase III trials (PRECiSE 1 and 2) of certolizumab pegol in moderate to severe active Crohn's disease. In addition, data from both trials suggest it is well-tolerated.

v • d • e

Humanized monoclonal antibodies

Alemtuzumab, Apolizumab, Aselizumab, Atlizumab, Bapineuzumab, Bevacizumab, Bivatuzumab mertansine, Cantuzumab mertansine, Cedelizumab, Certolizumab pegol, Cidfusituzumab, Cidtuzumab, Daclizumab, Eculizumab, Efalizumab, Epratuzumab, Erlizumab, Felvizumab, Fontolizumab, Gemtuzumab ozogamicin, Inotuzumab ozogamicin, Labetuzumab, Lintuzumab, Matuzumab, Mepolizumab, Motavizumab, Motovizumab, Natalizumab, Nimotuzumab, Nolovizumab, Numavizumab, Ocrelizumab, Omalizumab, Palivizumab, Pascolizumab, Pecfusituzumab, Pectuzumab, Pertuzumab, Pexelizumab, Ralivizumab, Ranibizumab, Reslivizumab, Reslizumab, Resyvizumab, Rovelizumab, Ruplizumab, Sibrotuzumab, Siplizumab, Sontuzumab, Tacatuzumab tetraxetan, Tadocizumab, Talizumab, Tefibazumab, Tocilizumab, Toralizumab, Trastuzumab, Tucotuzumab celmoleukin, Tucusituzumab, Umavizumab, Urtoxazumab, Visilizumab